[{"id":"1330d05c-ce55-45d8-aef6-64434dd03682","acronym":"IL Believe","url":"https://clinicaltrials.gov/study/NCT05081609","created_at":"2021-10-18T12:53:10.136Z","updated_at":"2025-02-25T16:45:39.607Z","phase":"Phase 1/2","brief_title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","source_id_and_acronym":"NCT05081609 - IL Believe","lead_sponsor":"Ascendis Pharma Oncology Division A/S","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Kadcyla (ado-trastuzumab emtansine) • onvapegleukin alfa (TransCon IL-2 β/γ) • resiquimod SR (TransCon TLR7/8 Agonist)"],"overall_status":"Recruiting","enrollment":" Enrollment 345","initiation":"Initiation: 01/11/2022","start_date":" 01/11/2022","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2025-02-05"}]